Anirban Adhikary1*, Kakoli Halder1, Debmalya Ghosh1, Snehansu Biswas2, Indranil Chatterjee2 and Suman Kumar Nath2
1B. Pharm, Birbhum Pharmacy School, Birbhum, West Bengal, India
2Assistant Professor, Birbhum Pharmacy School, Birbhum, West Bengal, India
*Corresponding Author: Anirban Adhikary, B. Pharm, Birbhum Pharmacy School, Birbhum, West Bengal, India.
Received: August 27, 2020; Published: October 15, 2020
The SARS-CoV-2 infection rose in December 2019 and afterward spread quickly around the world, especially to China, Japan and South Korea. Researchers are attempting to discover antivirals explicit to the infection. Some drugs Such as arbidol, chloroquine, remdesivir and favipiravir are right as of now experiencing clinical evaluations to test their sensibility and security in the treatment of coronavirus disease 2019 (COVID-19) in China, some consoling results have been developed up until now. This article sums up specialists with expected viability against SARS-CoV-2..
Keywords: Chloroquine; Pneumonia; COVID-19; SARS-CoV-2; Pandemic; Out Break; Antivirals
Citation: Anirban Adhikary., et al. “A Review of Ongoing Trials to Treat COVID-19". Acta Scientific Microbiology 3.11 (2020): 35-38.
Copyright: © 2020 Anirban Adhikary., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.